| Methods |
2‐ to 4‐week washout; 2‐week single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 95‐114 mm Hg and did not vary by more than 10 mm Hg for each of three visits during run‐in; 10‐week total double‐blind treatment, patients initially received tasosartan 50 mg once daily initially, this dose was titrated to 100 mg at end of week 3 and to 200 mg at end of week 6, until efficacy was achieved (defined as mean trough sitting DBP of 90 mm Hg or less) |
| Participants |
Tasosartan 50 mg: n=132(88 males, 44 females); mean age=52.2(9.6) years; baseline sitting SBP=150.6(13.8) mm Hg, DBP=100.3(8.0) mm Hg;
Placebo: n=130(92 males,38 females); mean age=52.5(9.7) years; baseline sitting SBP=150.1(13.7) mm Hg, DBP=100.3(8.0) mm Hg |
| Interventions |
Tasosartan 50 mg once daily;
Placebo;
taken as close to 8:30 AM as possible |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP |
| Notes |
Used week 3 BP data only; BP and SD of change reported, endpoint BP and SD not reported; BP measurement device not reported; DBP data from Figure 1, p. 120; SBP data from Figure 2, p. 120; Jadad score=2; funding source= Wyeth Ayerst Research |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
